Newsletter | November 5, 2025

11.05.25 -- The Business Case For Health Economics And Outcomes Research

FEATURED ARTICLE

The Business Case For Health Economics And Outcomes Research

On this episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and outcomes research (HEOR), and not just with patients and commercial payers.

INDUSTRY INSIGHTS

5 Common Misconceptions About Mobile Visits In Clinical Trials

Mobile research nurses are becoming integral to supporting complex protocols in global clinical trials, especially as decentralized approaches gain traction. Review key misconceptions about mobile research services.

The Healing Power Of Support Groups

Support groups offer emotional strength and connection for patients and caregivers, helping them navigate medical challenges, treatment journeys, and the complexities of chronic conditions.

New AI Assistant Aids In Clinical Settings

Discover a new AI Copilot that revolutionizes clinical data analysis and offers seamless deployment with intuitive question-answering, chart generation, and content integration.

Clinical Trial Payments And Ethics: Your Top Questions Answered

Gain a deeper understanding of the rationale behind different aspects of trial payments, and find tactical guidelines to put into place and use to educate your organization.

How To Select And Implement The Right ERP System For Life Sciences Companies

Wondering if your company is ready for a new ERP system? Find insights on ERP readiness, smooth implementation, and finding a partner who truly understands life sciences.

FUJIFILM Biotechnologies Cuts The Ribbon On New Holly Springs Facility

A new Holly Springs facility boosts U.S. biologics manufacturing with end-to-end capabilities and supply chain resilience—marking a major investment in North Carolina’s life sciences infrastructure.

How High Drug Load Nanocrystalline Tablets Lower Pill Burden

We showcase the development of high drug load nanocrystal based tablets and prove that nanocrystals can match the pharmacokinetic performance of ASDs while reducing the overall pill burden.